Total Payments
$6,727
2023 Payments
$13.84
Companies
11
Transactions
62
Medicare Patients
2,396
Medicare Billing
$101,935
Payment Breakdown by Category
Research$4,329 (64.3%)
Travel$1,204 (17.9%)
Food & Beverage$984.53 (14.6%)
Education$210.24 (3.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,329 | 21 | 64.3% |
| Travel and Lodging | $1,204 | 7 | 17.9% |
| Food and Beverage | $984.53 | 31 | 14.6% |
| Education | $210.24 | 3 | 3.1% |
Payments by Type
Research
$4,329
21 transactions
General
$2,398
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,602 | 19 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,755 | 15 | $0 (2018) |
| Noven Pharmaceuticals, Inc. | $1,726 | 2 | $0 (2017) |
| Amgen Inc. | $261.18 | 7 | $0 (2019) |
| Merz North America, Inc. | $189.95 | 5 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $44.49 | 3 | $0 (2018) |
| AbbVie Inc. | $41.82 | 3 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $34.70 | 3 | $0 (2018) |
| Lilly USA, LLC | $27.27 | 2 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.15 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $13.84 | 1 | AbbVie Inc. ($13.84) |
| 2022 | $13.32 | 1 | ABBVIE INC. ($13.32) |
| 2019 | $68.95 | 5 | Celgene Corporation ($16.46) |
| 2018 | $540.67 | 18 | Amgen Inc. ($248.97) |
| 2017 | $6,090 | 37 | GlaxoSmithKline, LLC. ($2,602) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/19/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: ONCOLOGY | ||||||
| 05/19/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2019 | Merz North America, Inc. | — | Food and Beverage | Cash or cash equivalent | $11.50 | General |
| 03/29/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Virology | ||||||
| 01/14/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Hematology / Oncology | ||||||
| 01/04/2019 | Amgen Inc. | Neulasta (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: Oncology | ||||||
| 12/13/2018 | Amgen Inc. | — | Education | In-kind items and services | $99.00 | General |
| 12/13/2018 | Amgen Inc. | — | Education | In-kind items and services | $95.00 | General |
| 12/06/2018 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Oncology | ||||||
| 11/23/2018 | Merz North America, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.44 | General |
| 11/17/2018 | Merz North America, Inc. | XEOMIN (Biological), ASCLERA | Food and Beverage | Cash or cash equivalent | $127.60 | General |
| Category: DERMATOLOGY | ||||||
| 10/25/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.30 | General |
| Category: Oncology | ||||||
| 10/18/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.37 | General |
| Category: Oncology | ||||||
| 10/05/2018 | Amgen Inc. | — | Education | In-kind items and services | $16.24 | General |
| 10/05/2018 | Amgen Inc. | Neulasta (Biological), NEUPOGEN, Vectibix | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Oncology | ||||||
| 09/06/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.82 | General |
| Category: Oncology | ||||||
| 08/17/2018 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $10.49 | General |
| Category: Hematology | ||||||
| 07/20/2018 | Amgen Inc. | Neulasta (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Oncology | ||||||
| 06/29/2018 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Oncology | ||||||
| 06/06/2018 | Novartis Pharmaceuticals Corporation | FEVIPIPRANT (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| 05/24/2018 | Merz North America, Inc. | XEOMIN (Biological) | Food and Beverage | Cash or cash equivalent | $9.21 | General |
| Category: DERMATOLOGY | ||||||
| 02/05/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS OA OF THE KNEE. | Noven Pharmaceuticals, Inc. | $1,726 | 2 |
| A 24 month double blind randomised parallel group study to determine the effect of Anoro on symptoms vs Tiotropium | GlaxoSmithKline, LLC. | $1,588 | 10 |
| A Phase IIb, Randomized Stratified , Double Blind Sponsor Open , Parallel Group, Placebo Controlled, Dose Finding Study of Nemiralisib GSK2269557 Added to Standard of Care SoC Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Seve | GlaxoSmithKline, LLC. | $852.93 | 7 |
| A PHASE IIB, RANDOMIZED (STRATIFIED), DOUBLE-BLIND (SPONSOR OPEN), PAR | GlaxoSmithKline, LLC. | $161.56 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 5 | 2,396 | 2,441 | $228,602 | $101,935 |
Total Patients
2,396
Total Services
2,441
Medicare Billing
$101,935
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2020 | 1,157 | 1,177 | $117,700 | $59,837 | 50.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 860 | 882 | $74,970 | $26,026 | 34.7% |
| 86328 | Ia nfct ab sarscov2 covid19 | Office | 2020 | 317 | 318 | $31,500 | $14,380 | 45.6% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 47 | 49 | $2,107 | $893.20 | 42.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 15 | $2,325 | $799.94 | 34.4% |
About Dr. David Bouda, MD
Dr. David Bouda, MD is a Medical Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912021635.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Bouda, MD has received a total of $6,727 in payments from pharmaceutical and medical device companies, with $13.84 received in 2023. These payments were reported across 62 transactions from 11 companies. The most common payment nature is "" ($4,329).
As a Medicare-enrolled provider, Bouda has provided services to 2,396 Medicare beneficiaries, totaling 2,441 services with total Medicare billing of $101,935. Data is available for 1 year (2020–2020), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Kansas City, MO
- Active Since 03/19/2007
- Last Updated 02/14/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1912021635
Products in Payments
- ANORO (Drug) $1,588
- FEVIPIPRANT (Drug) $499.18
- XEOMIN (Biological) $136.81
- OPDIVO (Biological) $44.49
- Neulasta (Biological) $40.45
- CYRAMZA (Drug) $27.27
- VENCLEXTA (Drug) $27.16
- GILOTRIF (Drug) $27.15
- XOLAIR (Biological) $26.23
- KEYTRUDA (Biological) $23.81
- Revlimid (Drug) $16.46
- Venclexta (Drug) $14.66
- Xeomin (Biological) $14.20
- Nplate (Biological) $10.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Kansas City
Dr. Timothy Pluard, Md, MD
Medical Oncology — Payments: $770,178
Medical Oncology $770,178
Dr. Amandeep Kalra, M.d, M.D
Medical Oncology — Payments: $22,301
Medical Oncology $22,301
Mrs. Shajadi Patan, M.d, M.D
Medical Oncology — Payments: $6,158
Medical Oncology $6,158
Sreekanth Donepudi, Md , Mph, MD , MPH
Medical Oncology — Payments: $3,761
Medical Oncology $3,761
Dr. Allan Fleming, M.d, M.D
Medical Oncology — Payments: $19.81
Medical Oncology $19.81